*	OR T2 T3
R1	AND Arg1:T1 Arg2:T2	
*	OR T5 T6
R2	Has_temporal Arg1:T5 Arg2:T7	
R3	AND Arg1:T10 Arg2:T9	
R4	Has_value Arg1:T12 Arg2:T13	
R5	Subsumes Arg1:T11 Arg2:T12	
R6	AND Arg1:T17 Arg2:T16	
R7	Has_temporal Arg1:T17 Arg2:T18	
R8	Has_temporal Arg1:T20 Arg2:T19	
R9	Has_temporal Arg1:T20 Arg2:T21	
R10	Has_temporal Arg1:T22 Arg2:T23	
R11	Has_mood Arg1:T22 Arg2:T24	
R12	AND Arg1:T25 Arg2:T26	
R13	Has_qualifier Arg1:T27 Arg2:T28	
*	OR T29 T30
R14	Subsumes Arg1:T27 Arg2:T29	
R15	Has_value Arg1:T35 Arg2:T36	
R16	Has_qualifier Arg1:T34 Arg2:T33	
R17	Subsumes Arg1:T34 Arg2:T35	
R18	Has_qualifier Arg1:T41 Arg2:T42	
*	OR T39 T40 T41 T43
*	OR T43 T44
R19	Has_value Arg1:T43 Arg2:T45	
R20	Has_qualifier Arg1:T48 Arg2:T49	
R21	AND Arg1:T51 Arg2:T50	
*	OR T53 T54 T55
R22	Has_value Arg1:T56 Arg2:T57	
T1	Condition 0 17	Contraindications
T2	Drug 21 34	empagliflozin
T3	Drug 36 47	Sitagliptin
T5	Drug 49 64	DPP4 inhibitors
T6	Drug 68 116	Sodium-glucose cotransporter-2(SGLT2) inhibitors
T7	Temporal 117 144	within the previous 4 weeks
T9	Drug 146 153	Insulin
T10	Procedure 164 172	diabetes
T11	Condition 174 194	Poor glucose control
T12	Measurement 196 201	HbA1C
T13	Value 201 206	>10 %
T15	Condition 209 232	Acute coronary syndrome
T16	Device 234 239	Stent
T17	Procedure 240 249	placement
T18	Temporal 250 278	within the previous 6 months
T19	Temporal 326 354	within the previous 6 months
T20	Procedure 289 325	coronary artery bypass graft surgery
T21	Temporal 280 288	Previous
T22	Procedure 364 381	revascularization
T23	Temporal 382 397	within 6 months
T24	Mood 356 363	Planned
T25	Condition 399 412	Heart failure
T26	Drug 423 437	loop diuretics
T27	Condition 446 474	left ventricular hypertrophy
T28	Qualifier 439 445	Severe
T29	Measurement 476 514	left ventricular septal wall thickness
T30	Value 515 521	> 13mm
T33	Qualifier 524 535	Significant
T34	Condition 536 549	renal disease
T35	Measurement 564 584	creatinine clearance
T36	Value 588 599	< 30 ml/min
T39	Condition 602 617	Hepatic disease
T40	Condition 621 646	biliary tract obstruction
T41	Condition 663 687	hepatic enzyme elevation
T42	Qualifier 651 662	significant
T43	Measurement 689 709	alanine transaminase
T44	Measurement 713 739	Aspartate Aminotransferase
T45	Value 740 771	> 3 times upper limit of normal
T48	Device 774 793	Radiopaque material
T49	Qualifier 811 821	chest wall
T50	Procedure 867 888	adenosine stress test
T51	Condition 847 863	Contraindication
T52	Post-eligibility 890 1113	Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
T53	Condition 1125 1133	pregnant
T54	Condition 1137 1151	breast-feeding
T55	Condition 1155 1178	child-bearing potential
T56	Observation 1180 1204	Expected life expectancy
T57	Value 1205 1213	< 1 year
T58	Non-query-able 1215 1298	Unwillingness or inability to comply with the procedures described in this protocol
